Thompson Investment Management Inc. Boosts Stock Position in Pfizer Inc. $PFE

Thompson Investment Management Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 8.3% during the fourth quarter, Holdings Channel reports. The firm owned 463,455 shares of the biopharmaceutical company’s stock after acquiring an additional 35,325 shares during the period. Pfizer makes up approximately 1.4% of Thompson Investment Management Inc.’s portfolio, making the stock its 16th largest position. Thompson Investment Management Inc.’s holdings in Pfizer were worth $11,540,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Enterprise Financial Services Corp lifted its holdings in shares of Pfizer by 7.9% during the fourth quarter. Enterprise Financial Services Corp now owns 25,273 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 1,842 shares during the period. Goelzer Investment Management Inc. increased its holdings in Pfizer by 1.3% in the 4th quarter. Goelzer Investment Management Inc. now owns 178,841 shares of the biopharmaceutical company’s stock worth $4,453,000 after buying an additional 2,340 shares during the period. Spire Wealth Management raised its position in Pfizer by 1.4% during the 4th quarter. Spire Wealth Management now owns 46,977 shares of the biopharmaceutical company’s stock worth $1,170,000 after buying an additional 655 shares during the last quarter. Chesley Taft & Associates LLC lifted its stake in Pfizer by 41.3% during the 4th quarter. Chesley Taft & Associates LLC now owns 208,557 shares of the biopharmaceutical company’s stock valued at $5,193,000 after acquiring an additional 60,956 shares during the period. Finally, Woodward Diversified Capital LLC lifted its stake in Pfizer by 2.1% during the 4th quarter. Woodward Diversified Capital LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 623 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. Finally, Citigroup began coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Performance

PFE opened at $27.03 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a fifty day moving average price of $26.84 and a 200 day moving average price of $25.70. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The stock has a market cap of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business earned $0.63 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.